Identity
Sanofi Aventis, S.A.
| Year | Amount | Distribution |
|---|---|---|
| 2026* | €156.0M | |
| 2025 | €231.0M | |
| 2024 | €136.9M | |
| + regional platforms | ||
| 2023 | €120.5M | |
| 2022 | €54.8M | |
| 2021 | €49.1M | |
| 2020 | €27.0M | |
| 2019 | €17.1M | |
| 2018 | €8.1M | |
| 2017 | €2.4M | |
| 2016 | €0.2M | |
In figures
Volume
Between 2016 and 2026 it won 1,377 contracts worth €803M on its own, with 77 buyers. Its 12 joint-venture (UTE) contracts are shown separately.
Price
In 2024–2026 its median discount was 32.0%; the middle half of its discounts between 25.7% and 40.5% (19 comparable awards).
Competition
Since 2024, 36% of its comparable value was won with a discount and against other bidders. It was the only bidder in 80% of its contracts (2016–2026).
Renewals
94 contracts (€71.8M) come up for tender again in the next 24 months.
A UTE is a temporary joint venture: the contract is awarded to the UTE and each partner's share is not published. That is why these contracts are not added to Sanofi Aventis, S.A.'s total, and under «Show UTEs» the amounts are the full value of each contract (100%), not Sanofi Aventis, S.A.'s share.
Data up to 31 October 2026 · updated on 12 November 2026 · Source: official data, national and regional coverage
| UTE partners | Contracts | Total value (100 %) |
|---|
Its discounts
The discount at which it wins contested contracts, year by year.
2024–2026: median 32.0% · middle half between 25.7% and 40.5% · 19 awards
2019–2023: median 19.9% (25 awards) · 2024–2026: median 32.0% (19 awards).
2019–2026: median 29.7% · middle half between 12.7% and 38.8% · 44 awards
Discount on the tender budget, excluding VAT, on awards above the minor-contract threshold · Source: official data, national and regional coverage. Methodology →
Where it wins, and at what discount
In the report · these discounts, one by one
Each dot on the chart is an award. The report lists them all and groups them by buyer and by sector, next to the discounts of other companies with the same buyers.
By sector
Productos farmacéuticos
CPV 336
746 contracts · €523M
By buyer · 2024–2026
Departament de Salut
Productos farmacéuticos
32 contracts · €76.2M
Full list: date, buyer, amount, budget, discount, bidders and a link to the official publication.
19 awards at the tender price, left out of the discounts.
How it wins
Whether it wins with or without competition.
38% of the comparable value since 2024 (€11.5M of €30.2M) was won at the tender price and without other bidders. €11.0M (36%) was awarded with a discount and against other bidders.
Comparable: 59 awards with a published budget and bidder count (€30.2M of €524M awarded since 2024). Percentages of value; the figure next to «bidders» is the number of awards. Source: official data, national and regional coverage.
Between 2016 and 2026, 61.9% of the value was awarded through negotiated without publicity procedure (39.5% of contracts); followed by Open (17.8%) and Other (11.3%).
Upcoming tenders and main buyers
When its contracts come back and who it sells to.
In the next 24 months 94 of its contracts come up for tender again, worth €71.8M.
| Expected end | Buyer | Value |
|---|---|---|
| 2026 | Hospital Universitario de Fuenlabrada | €267k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €169k |
| 2026 | Dirección Gerente del Hospital Universitario Nuestra Señora de Candelaria | €39.8k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €24.1k |
| 2026 | Gerencia de Servicio Sanitarios de Fuerteventura | €4.82k |
and 89 more in the next 24 months · the report includes them all
Expected end year from the published duration (no extensions). The report includes the month and the discount it won each one at.
| Buyer | Contracts | Value, € | Period |
|---|---|---|---|
| Departament de Salut | 62 | 133 M | 2020–2026 |
| Servicio Andaluz de Salud | 143 | 127 M | 2024–2026 |
| Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad | 35 | 83 M | 2019–2026 |
| Gerencia de Servicio Sanitarios de Fuerteventura | 477 | 62 M | 2018–2026 |
| OSAKIDETZA - Servicio Vasco de Salud -Director General | 15 | 52 M | 2024–2026 |
and 72 more buyers
Between 2016 and 2026, 100.0% of the value it won on its own is in Medical & pharmaceuticals (CPV 33, 1,362 contracts).
Recent awards
The evidence behind every insight in the report.
| Date | Contract | Buyer | Bidders | Value |
|---|---|---|---|---|
| 11/08/2026 | Adquisición de 200.000 dosis de la Vacuna inactivada producida a partir de virus crecido en huevos … | Dirección General de Planificación Económica | 1 | €3.50M |
| 11/08/2026 | Adquisición de 85.000 dosis de la Vacuna inactivada producida a partir de virus crecido en huevos e… | Dirección General de Planificación Económica | 2 | €383k |
| 07/08/2026 | Suministro de vacunas en el edificio del Paseo del Prado, 18-20 de Madrid. LOTE 4 | Subdirección General de la Oficina Presupuestaria y Gestión Económica | 1 | €20.0 |
| 15/06/2026 | cbam-3 sanofi aventisexp. 786/2023 vacuna combinada hexavalente | Servicio Andaluz de Salud | 1 | €109k |
| 05/06/2026 | 1º cbam sanofi aventis s.a. am 578/2025 para la central de compras de almería | Servicio Andaluz de Salud | 1 | €700k |